ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.66 and traded as high as $6.89. ImmuCell shares last traded at $6.70, with a volume of 1,783 shares trading hands.
ImmuCell Price Performance
The company has a quick ratio of 2.21, a current ratio of 4.12 and a debt-to-equity ratio of 0.30. The firm's 50-day moving average is $6.57 and its 200-day moving average is $5.68. The company has a market cap of $54.47 million, a PE ratio of -86.06 and a beta of 0.32.
ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%. The firm had revenue of $8.07 million for the quarter.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in ICCC. Northern Trust Corp raised its position in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the period. Citadel Advisors LLC purchased a new stake in shares of ImmuCell in the fourth quarter worth $149,000. Geode Capital Management LLC grew its stake in ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after acquiring an additional 7,878 shares in the last quarter. Finally, Dauntless Investment Group LLC purchased a new position in ImmuCell during the fourth quarter valued at $676,000. Institutional investors own 13.47% of the company's stock.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Articles
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access